How Could Retatrutide Reshape Global Peptide API Demand After Phase III Success?

Over the past five years, the global weight-loss drug market has evolved from GLP-1 single-target therapies to dual-target mechanisms, driving peptides from early research into large-scale commercial development. With Eli Lilly and Company announcing Phase…











